Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Cell Oncol (Dordr). 2024 Jun;47(3):759-777. doi: 10.1007/s13402-023-00912-8. Epub 2024 Jan 31.
In the past decades, cancer enigmatical heterogeneity at distinct expression levels could interpret disparities in therapeutic response and prognosis. It built hindrances to precision medicine, a tactic to tailor customized treatment informed by the tumors' molecular profile. Single-omics analysis dissected the biological features associated with carcinogenesis to some extent but still failed to revolutionize cancer treatment as expected. Integrated omics analysis incorporated tumor biological networks from diverse layers and deciphered a holistic overview of cancer behaviors, yielding precise molecular classification to facilitate the evolution and refinement of precision medicine.
This review outlined the biomarkers at multiple expression layers to tutor molecular classification and pinpoint tumor diagnosis, and explored the paradigm shift in precision therapy: from single- to multi-omics-based subtyping to optimize therapeutic regimens. Ultimately, we firmly believe that by parsing molecular characteristics, omics-based typing will be a powerful assistant for precision oncology.
在过去的几十年中，不同表达水平的癌症复杂异质性可以解释治疗反应和预后的差异。这为精准医学制造了障碍，精准医学是一种根据肿瘤分子特征量身定制治疗方案的策略。单组学分析在一定程度上剖析了与癌变相关的生物学特征，但仍未能如预期那样彻底改变癌症治疗。整合组学分析从不同层面整合了肿瘤生物学网络，破译了癌症行为的整体概况，实现了精确的分子分类，从而促进了精准医学的发展和完善。
本综述概述了多个表达层的生物标志物，以指导分子分类和确定肿瘤诊断，并探讨了精准治疗的范式转变：从基于单组学到基于多组学的亚分型，以优化治疗方案。最终，我们坚信，通过解析分子特征，基于组学的分型将成为精准肿瘤学的有力助手。
